Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599412 | 0.88 | HRH4 (0.60) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL3643672 | 0.87 | HPGD (0.54) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL10085548 | 0.85 | HRH4 (0.61) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL30314640 | 0.85 | HRH4 (0.58) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL31287830 | 0.84 | KMT2A (0.72) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL3635965 | 0.83 | PIN1 (0.63) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL29709913 | 0.83 | PIN1 (0.63) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL12042716 | 0.82 | KDM4E (0.54) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL22803292 | 0.82 | EPHX2 (0.56) | KDM4EHPGDHSD17B10ALDH1A1PDPK1 | |
| SCHEMBL16236301 | 0.81 | HRH4 (0.57) | KDM4EHPGDHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115427404-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-117751124-A | Spiro oxindole compounds and application thereof in preparing antiviral protease inhibitor medicines | 南京药石科技股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117396485-A | PARP7 inhibitors | 轩竹生物科技股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023109926-A1 | SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG | 南京药石科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-1910335-A1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| EP-1841737-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007010144-A1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006072736-A1 | N- (HETEROARYL) -1H-INDOLE-2-CARB0XAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2006-07-13 | — | — | WO | disclosed |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1445250-A1 | NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | KDM4E 3048/4885HPGD 176/4885HSD17B10 297/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | KDM4E 1129/4885HPGD 3962/4885HSD17B10 700/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | KDM4E 4720/4885HPGD 347/4885HSD17B10 1735/4885 |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | TPSAB1, TPSB2, TPSD1 | KDM4E 1687/4885HPGD 1220/4885HSD17B10 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.